First Patient Treated with Proton Therapy at Lynn Cancer Institute - Report - MDSpire
Advertisement
First Patient Treated with Proton Therapy at Lynn Cancer Institute
The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.
Clinical Report: First Patient Treated with Proton Therapy at Lynn Cancer Institute
Overview
The Lynn Cancer Institute has successfully treated its first patient with proton therapy, marking a significant advancement in local cancer care. This milestone reflects the collaborative efforts of multidisciplinary teams to provide highly targeted radiation treatment options.
Background
Proton therapy represents a cutting-edge approach in radiation oncology, offering precise tumor targeting while minimizing damage to surrounding healthy tissues. Its availability at the Lynn Cancer Institute enhances treatment options for patients in South Palm Beach County, particularly for complex cases involving sensitive organs. This development underscores the importance of innovation and collaboration in improving cancer care.
Data Highlights
No numerical data available in the source material.
Key Findings
The first patient treated with proton therapy was identified as an ideal candidate through collaboration between a neurosurgeon and radiation oncologists.
Proton therapy minimizes radiation exposure to healthy tissues, which is crucial for tumors near sensitive organs.
The treatment decision was based on a thorough clinical evaluation and coordination among the patient's care team.
Philanthropic support from the community played a vital role in establishing the Proton Therapy Center at the Lynn Cancer Institute.
This milestone signifies a new chapter in cancer treatment for the South Florida community, enhancing access to advanced therapies.
Clinical Implications
Expand on how clinicians can implement proton therapy in practice, including potential patient selection criteria.
Conclusion
Reiterate the significance of this milestone for the community and future cancer care advancements.
Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.
